Allergan, Inc. (AGN): This Stock Waits to Exhale

Allergan, Inc. (NYSE:AGN) announced today that the Food and Drug Administration issued a complete response letter for Levadex, an inhalable drug that treats migraines. The company had warning of the FDA’s concerns — which focused not on safety issues but on the drug’s manufacturing process — and has worked to address these problems.

What does this new CRL mean for Levadex’s future?

Allergan, Inc. (NYSE:AGN)

Solving through acquisition
An inspection had turned up a quality issue at the Exemplar Pharma-owned facility that filled the Levadex canisters. So Allergan, Inc. (NYSE:AGN) purchased Exemplar for approximately $20 million and installed its own people for better oversight. The CRL expressed problems with the manufacturing of the completed canisters, but Allergan says the company has already responded and awaits the FDA’s review.

It wasn’t the first manufacturing CRL that Allergan, Inc. (NYSE:AGN) has received — or the first acquisition in the name of pushing Levadex toward market. In January, Allergan inhaled its Levadex partner MAP Pharmaceuticals for about $958 million.

Now what?
The FDA will likely perform another inspection on Exemplar, but Allergan, Inc. (NYSE:AGN)’s still anticipating a decision in the fourth quarter of this year. Levadex won’t suffer a large delay if that timeline holds true, and the setback shouldn’t affect Allergen’s 2013 revenues.

Levadex could still make it to market next year, joining Allergan’s own Botox injection, which has approvals around the world for treating chronic migraines. Levadex won’t become the first inhalable migraine drug to market — Valeant’s Migranal nasal spray has been out for years. But Allergan, Inc. (NYSE:AGN)’s drug has shown better efficacy.

Allergan can bide its time to approval with its successful approved products. These include the aforementioned Botox, with a predicted $2 billion in revenues this year, and the $870 billion prescription eye drops Restasis.

Foolish final thoughts
It seems that the FDA wants Allergan, Inc. (NYSE:AGN) to iron out these last manufacturing problems before Levadex receives approval. Fortunately for investors, Allergan has other blockbuster products to rely on while this process finishes. And Levadex could end up finding a decent market of migraine sufferers looking for a convenient and effective treatment if it eventually wins approval.

The article Allergan Waits to Exhale originally appeared on Fool.com is written by Brandy Betz .

Fool contributor Brandy Betz and The Motley Fool have no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Most Successful Reality TV Stars

Cheapest Cities to Visit in the US

Most Expensive Summer Camps

Most Expensive Animals in the World

Most Expensive Specialty Crops in the World

Movies That Took Ages to Make

The Longest Hollywood Films Ever Made

Most Expensive Concert Stages

The Richest Bands of all Time

10 Most Corrupt Countries 2013 List

10 Countries with the Highest Quality of Life Index

Most Expensive Mattresses in the World

5 Smallest Countries by Land Area

The Ultimate Heartbreak Songs

Richest Teenagers in the World

10 Most Haunted Places in America

10 Best Places to Retire in Florida East Coast

Top 10 Places to See Before You Die

Top 8 Countries in the World Where Justice Prevails

10 Richest States in America

15 Wealthiest Countries in the World

Richest Singers in the World

Most Expensive Tasting Menu in New York City

Most Expensive Baby Items in the World

Most Expensive Hotel Suites in Vegas

Most Expensive Brunch in New York City

Most Expensive Beef Cuts in the World

25 Best Colleges to Get a Job

Top 10 US Supermarkets

The 25 Most Dangerous Cities in the World to Visit

Most Expensive Xbox Games

Top 11 Cities Where Billionaires Live

Top 10 Most Charitable Companies in America

Most Expensive Seafood in the World

The 10 Wildest Conspiracy Theories

The 10 Best Job Markets in the US

Top 10 Accounting Scandals of All Time

The 25 Biggest Cities in the World

Top 10 Best Paying Virtual Jobs

Most Expensive Leather Shoes in the World

Top 6 Things to Buy in March

The 10 Most Stressful Jobs in America – 2014 List

Top 10 Jobs for Introverted People

Top 10 Honeymoon Destinations in the World

Top 10 Highest Paying Jobs in the World

Most Expensive Day-Care in New York City

The 10 Cheapest Places to Retire Abroad

Top 10 Most Expensive Luxury Cars in the World – 2014

Killer Small Business Ideas

The 50 Best Personal Finance Blogs

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!